Profile
Dr. Martin D.
Meglasson is Chief Scientific Officer & Vice President at Bellerophon Therapeutics, Inc.
Dr. Meglasson was previously employed as Chief Scientific Officer by Ikaria, Inc., Vice President-Discovery Research by Ligand Pharmaceuticals, Inc., a Director-Preclinical Pharmacology by Pharmacia, Inc., and a Director-Endocrine & Metabolic Research by Pharmacia & Upjohn, Inc.
He received his doctorate degree from the University of Houston.
Former positions of Martin D. Meglasson
| Companies | Position | End |
|---|---|---|
| IKARIA, INC. | Chief Tech/Sci/R&D Officer | 31/12/2013 |
| LIGAND PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 22/07/2010 |
| Pharmacia, Inc. | Chief Tech/Sci/R&D Officer | 31/12/2002 |
| Pharmacia & Upjohn, Inc. | Corporate Officer/Principal | 31/12/1997 |
| BELLEROPHON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Martin D. Meglasson
| University of Houston | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| BELLEROPHON THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
| Pharmacia & Upjohn, Inc. | Health Technology |
| Pharmacia, Inc. | |
Ikaria, Inc.
 Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
- Stock Market
- Insiders
- Martin D. Meglasson
